TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7899788
Drug: Albendazole administered
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole administered 5-7 days after ivermectin
Study: 3110848
Drug: d-amphetamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (0.5 mg/kg PO)
Study: 29116126
Drug: Clinical predictors
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical predictors including demographics, anthropometrics, cardiac and blood measures, diet and exercise, physical and mental health, medication
Study: 29116126
Drug: Genetic polygenic
Normalized name: polygalic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetic polygenic risk scores (PRS) for schizophrenia, bipolar disorder, BMI, waist‐hip‐ratio, insulin resistance and height, gene co‐expression modules from WGCNA
Study: 23331081
Drug: Buccal infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal infiltration (BI) group: 40 patients received supplemental BI of 0.9 mL of 4% articaine with 1 : 100,000 epinephrine.
Study: 23331081
Drug: Buccal plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal plus lingual infiltration (BLI) group: 40 patients received supplemental BI of 0.9 mL of 4% articaine with 1 : 100,000 epinephrine and LIs with the same anaesthetic solution and dose.
Study: 17143239
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents (both types)
Study: 9387969
Drug: Tetracycline (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (1.5 g)
Study: 9387969
Drug: Bleomycin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin (60 mg)
Study: 7910473
Drug: Cimetidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (800 mg day‐1)
Study: 7910473
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg day‐1)
Study: 7910473
Drug: Famotidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (40 mg day‐1)
Study: 25716362
Drug: Whole-brain radiotherapy
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-brain radiotherapy (WBRT) after high-dose methotrexate (HDMTX)-based chemotherapy
Study: 25716362
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HDMTX)-based chemotherapy alone
Study: 21714640
Drug: Late initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Late initiation of parenteral nutrition (not initiated before day 8)
Study: 29570588
Drug: Late initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Late initiation of parenteral nutrition
Study: 21714640
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of parenteral nutrition (initiated within 48 hours after ICU admission)
Study: 15342289
Drug: Nesiritide infusions
Normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nesiritide infusions at dosages of 0.005 or 0.01 microg/kg/min for 12 weeks
Study: 1390333
Drug: Intravenous bepridil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bepridil (2 mg/kg)
Study: 1390333
Drug: Oral bepridil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bepridil (500 mg/day)
Study: 1390333
Drug: Oral bepridil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bepridil (900 mg/day)
Study: 1390333
Drug: Oral bepridil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bepridil (300 mg/day)
Study: 1390333
Drug: Oral bepridil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bepridil (600 mg/day)
Study: 3935405
Drug: Insulin-glibenclamide combination
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-glibenclamide combination therapy
Study: 30964413
Drug: Anopheles gambiae
Normalized name: ANOPHELES QUADRIMACULATUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anopheles gambiae s.l. in rural areas
Study: 29117299
Drug: High-dose triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose triamcinolone acetonide (40 mg)
Study: 29117299
Drug: Low-dose triamcinolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose triamcinolone acetonide (20 mg)
Study: 8659199
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 80 mg/day
Study: 24851040
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of isosorbide dinitrate and ibuprofen
Study: 22892744
Drug: 2% gel
Normalized name: SULFUR 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% gel CHX
Study: 20159177
Drug: Continuous use
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous use of 30 mcg ethinylestradiol and 3 mg drospirenone for 168 days
Study: 20159177
Drug: Continuous use
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous use of 30 mcg ethinylestradiol and 3 mg drospirenone
Study: 20159177
Drug: Cyclic use
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic use of 30 mcg ethinylestradiol and 3 mg drospirenone for six 28‐day cycles
Study: 20159177
Drug: Cyclic use
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic use of 30 mcg ethinylestradiol and 3 mg drospirenone
Study: 17646619
Drug: 10-cm² rivastigmine
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10-cm² rivastigmine patch (9.5 mg/24 hours)
Study: 17646619
Drug: 20-cm² rivastigmine
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 20-cm² rivastigmine patch (17.4 mg/24 hours)
Study: 17646619
Drug: 6-mg BID
Normalized name: sarolaner 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-mg BID rivastigmine capsules
Study: 15789954
Drug: Corrective treatment
Normalized name: SALICYLIC ACID 0.5 mg in 90 mL TOPICAL CLOTH [Clear Future Corrective Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corrective treatment
Study: 9506733
Drug: Methimazole plus
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole plus T4 to suppress TSH below 0.6 mIU/L (group 3)
Study: 6579838
Drug: Intracervical application
Normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical application of 0.5 mg of prostaglandin E2 (PGE2) in 2 ml of gel
Study: 6579838
Drug: Intravaginal application
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal application of 4 mg of prostaglandin E2 (PGE2) in 3 ml of gel
Study: 31898663
Drug: 6 fractions/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 fractions/week of RT (46 Gy/23 fractions/26 days) with injection Cisplatin 40 mg/m2
Study: 31898663
Drug: 5 fractions/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 fractions/week of RT (46 Gy/23 fractions/31 days) with injection Cisplatin 40 mg/m2
Study: 26871847
Drug: Dexmedetomidine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1.0 μg/kg loading dose over 10 minutes, followed by 0.5 μg/kg/h maintenance)
Study: 18609169
Drug: Oral daily
Normalized name: Summer's Eve Sheer Floral Daily Cloths
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily treatment with 0.5 mg cyanocobalamin, 0.8 mg folic acid and 3 mg vitamin B(6) for 4 months
Study: 7599749
Drug: Enalapril (1.0-1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (1.0-1.2 mg intravenous over 1-2 hours)
Study: 1741918
Drug: 750 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg/d oxytetracycline over a fortnight
Study: 28397754
Drug: Colostrum bovinum
Normalized name: COLOSTRUM
DrugBank: Human colostrum (DB19286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colostrum bovinum supplementation (500 mg for 20 days)
Study: 19154574
Drug: Sci-B-Vac vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sci-B-Vac vaccine (2.5 microg)
Study: 19154574
Drug: Sci-B-Vac vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sci-B-Vac vaccine (5.0 microg)
Study: 19154574
Drug: Sci-B-Vac vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sci-B-Vac vaccine (2.5 microg or 5.0 microg)
Study: 15190957
Drug: IC14 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC14 (1 mg/kg or 4 mg/kg single doses; 4 mg/kg daily for 4 days; or 4 mg/kg on day 1 followed by 2 mg/kg daily for 3 days)
Study: 9886901
Drug: tasosartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: tasosartan (100 mg/day)
Study: 2308263
Drug: Propranolol (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (a nonselective beta-1, beta-2 antagonist) during exercise
Study: 2308263
Drug: Metoprolol (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (a specific beta-1 antagonist) during exercise
Study: 380256
Drug: Naproxen (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (250 mg, 1-2 tablets as needed, max 5 tablets daily)
Study: 29999203
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy with real-time visual feedback
Study: 29999203
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy without real-time visual feedback
Study: 25579161
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (G group, n=27)
Study: 16036036
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human BNP (nesiritide) as an intravenous treatment for acute decompensated HF
Study: 31286734
Drug: Acupoint thread-embedding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint thread-embedding therapy (operated once every 30 days, total of 2 treatments)
Study: 31286734
Drug: Topical artificial
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical artificial tears eye drops (4 to 6 times a day, one drop each time, for 8 weeks)
Study: 16753012
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg daily
Study: 26639957
Drug: Bapineuzumab 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bapineuzumab 0.5 mg/kg in carriers
Study: 26639957
Drug: Bapineuzumab 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bapineuzumab 1.0 mg/kg in noncarriers
Study: 26639957
Drug: Bapineuzumab 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bapineuzumab 0.5 mg/kg in noncarriers
Study: 23872837
Drug: Fruit-flavoured jelly
Normalized name: FLAVOR,FRUIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruit-flavoured jelly containing 4 g of agar crystals
Study: 20002369
Drug: 1000 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 microg of self‐administered vaginal misoprostol
Study: 20002369
Drug: Self‐administered vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐administered vaginal placebo
Study: 19025528
Drug: Epidural sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural sufentanil in ropivacaine (0.015 mcg/kg/ml sufentanil in 1.5 mg/ml ropivacaine, infused at 2 ml/h)
Study: 19025528
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl in ropivacaine (0.1 mcg/kg/ml fentanyl in 1.5 mg/ml ropivacaine, infused at 2 ml/h)
Study: 12860494
Drug: Nateglinide 60
Normalized name: nateglinide 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide 60 mg administered at -5 or -10 minutes relative to food
Study: 12860494
Drug: Nateglinide 60
Normalized name: nateglinide 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide 60 mg administered at -30 or -10 minutes
Study: 10371365
Drug: Sampatrilat (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sampatrilat (50 to 100 mg daily)
Study: 10371365
Drug: Lisinopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10 to 20 mg daily)
Study: 8904562
Drug: Ibuprofen (Ibu;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (Ibu; 1,200 mg/day)
Study: 1990938
Drug: M6 regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: M6 regimen (6 months of treatment with streptomycin, isoniazid, rifampin, and pyrazinamide)
Study: 1990938
Drug: M8 regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: M8 regimen (8 months of treatment with streptomycin, isoniazid, rifampin, and pyrazinamide)
Study: 6523889
Drug: Chemotherapy (B)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (B) and chemoimmunotherapy (C)
Study: 30994287
Drug: 8-time application,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-time application, each time 750 mL per plant (F1)
Study: 30994287
Drug: 12-time application,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-time application, each time 500 mL per plant (F2)
Study: 30994287
Drug: 16-time application,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16-time application, each time 375 mL per plant (F3)
Study: 30994287
Drug: Irrigating by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigating by 120% daily evapotranspiration (ET) before fruit enlargement, by 140%ET after fruit enlargement (W1)
Study: 30994287
Drug: F3W1 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: F3W1 treatment (16-time application with 120% ET before and 140% ET after)
Study: 30134291
Drug: Viral load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viral load suppression to less than 50 copies/ml
Study: 25176628
Drug: Midazolam administered
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam administered by cardiologist only
Study: 19947260
Drug: Medication acupoint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication acupoint sticking therapy (using cakes made of grinding pepper, brassica alba seeds, asarum, mixed with ginger oil and ginger juice)
Study: 17936213
Drug: Best available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Best available treatments
Study: 15199394
Drug: Prophylactic radiotherapy
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic radiotherapy with a single 10-Gy treatment using 9-MeV electrons
Study: 2752557
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg s.l.)
Study: 50181
Drug: Alcohol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (mean blood alcohol content of 90 mg%)
Study: 30295400
Drug: Morphine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (30 mg, subcutaneous, four-times daily) with naloxone (0.4 mg, IM) challenge
Study: 30295400
Drug: Clonidine, tramadol-ER,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine, tramadol-ER, and buprenorphine (RCT medications)
Study: 3657889
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of aspartame per kilogram of body weight
Study: 29902133
Drug: MMR-RIT vaccine
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR-RIT vaccine (Priorix, GSK)
Study: 29902133
Drug: MMR II
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR II vaccine (control; M-M-R II, Merck&Co Inc.)
Study: 21062996
Drug: Serp-1 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serp-1 (5 μg/kg)
Study: 21062996
Drug: Serp-1 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serp-1 (15 μg/kg)
Study: 18187530
Drug: MK-0343 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0343 0.75 mg
Study: 18187530
Drug: MK-0343 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0343 0.25 mg
Study: 14732977
Drug: PVP chemotherapy
Normalized name: PVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVP chemotherapy
Study: 9014295
Drug: DHEAS, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEAS, 50 mg po bid for 4 days, administered as an adjuvant to tetanus vaccination.
Study: 9014295
Drug: DHEAS administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEAS administered immediately before and 24 hours after influenza vaccination.
Study: 1362613
Drug: Cysteine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteine (200 mg 4 times daily)
Study: 1362613
Drug: MMSC (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMSC (500 mg 4 times daily)
Study: 1362613
Drug: Sulphasalazine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphasalazine (2 g daily) and Cysteine
Study: 1362613
Drug: Sulphasalazine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphasalazine (2 g daily) and MMSC
Study: 1362613
Drug: Sulphasalazine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphasalazine (2 g daily) alone
Study: 3161176
Drug: 0.3% foscarnet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% foscarnet cream
Study: 20702806
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BR; 0.5 l/day; 5.2 mmol of NO(3)(‐)/day)
Study: 18469091
Drug: Esomeprazole (ESO)
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole (ESO) 20 mg once daily (can be increased to 40 mg once daily or 20 mg twice daily)
Study: 12014516
Drug: 2 IU/m2/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 IU/m2/day of growth hormone (GH)
Study: 12014516
Drug: 4 IU/m2/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 IU/m2/day of growth hormone (GH)
Study: 12014516
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group (2 IU/m2/day)
Study: 12014516
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (4 IU/m2/day)
Study: 10081129
Drug: Sublingual glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual glycine application in daily dose of 1-2 g for 5 days, starting within the first 6 hours of stroke development.
Study: 7583388
Drug: Cessation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation of antibiotics regardless of ANC; initial treatment with ceftazidime +/- vancomycin for a median length of treatment of 3 days
Study: 31064965
Drug: Daily life-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily life-based physical activity enhancement program with one-on-one counseling, customized text messages, exercise diary, and mobile pedometer for 12 weeks
Study: 19303137
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg daily for 1 year
Study: 8647360
Drug: Oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide (n = 18)
Study: 8647360
Drug: Parenteral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Parenteral etoposide (n = 18)
Study: 1596044
Drug: Doxycycline-rifampin (DR)
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline-rifampin (DR) combination therapy
Study: 1596044
Drug: Doxycycline-streptomycin (DS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline-streptomycin (DS) combination therapy
Study: 1596044
Drug: Doxycycline-rifampin (DR)
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline-rifampin (DR) combination therapy excluding spondylitis patients
Study: 1596044
Drug: Doxycycline-streptomycin (DS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline-streptomycin (DS) combination therapy excluding spondylitis patients
Study: 6208807
Drug: 5% plasmaprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% plasmaprotein solution (PPS)
Study: 20189927
Drug: Concord grape
Normalized name: Concord Grape
DrugBank: Concord grape (DB10875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concord grape juice (4 oz. prior to meals for one week following each of four chemotherapy treatment cycles)
Study: 20189927
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 oz. prior to meals for one week following each of four chemotherapy treatment cycles)
Study: 18758386
Drug: Trimethoprim-sulfamethoxazole 18
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole 18 mg/kg twice daily
Study: 16190387
Drug: Ulinastatin 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin 1.2 x 10(4) U/kg (half dose intravenously after induction, half in primary solution)
Study: 12208645
Drug: Sustained-release ascorbic
Normalized name: ascorbic acid Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release ascorbic acid (3000 mg/day)
Study: 25980582
Drug: Daily tailored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily tailored text messaging for 90 days
Study: 22441104
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment group (ITG) with Peg IFNa-2a and ADV
Study: 22441104
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment group (STG) with Peg IFNa-2a monotherapy
Study: 22441104
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment group (ITG)
Study: 25100538
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment group (STG)
Study: 15855501
Drug: Alamifovir single
Normalized name: Alamifovir
DrugBank: Alamifovir (DB06368)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alamifovir single doses (0.2 to 80 mg), subset receiving 20 mg in a fed state
Study: 15855501
Drug: Alamifovir multiple
Normalized name: Alamifovir
DrugBank: Alamifovir (DB06368)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alamifovir multiple doses (2.5 to 15 mg twice daily for 15 days)
Study: 8951781
Drug: Non radio-mimetic
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non radio-mimetic agents (hydroxyurea or pipobroman)
Study: 8951781
Drug: Non radio-mimetic
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non radio-mimetic agents (hydroxyurea or pipobroman) in relatively young cases